Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Adare Pharmaceuticals Inc
Agile Therapeutics Inc
Dare Bioscience Inc
Evestra Inc
Exeltis Pharmaceuticals Holding SL
Herva Ltd
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
vad Life Sciences Pte Ltd
Orion Biotechnology Cada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc
Female Contraception - Drug Profiles
(dienogest + ethinylestradiol) PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(drospirenone + estetrol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(estradiol + segesterone acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ethinylestradiol + gestodene) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-200 SP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Contraception - Dormant Projects
Female Contraception - Discontinued Products
Female Contraception - Product Development Milestones
Featured News & Press Releases
May 20, 2020: Mithra and Searchlight Pharma announce filing of New Drug Submission for Estelle in Cada
Apr 22, 2020: MedinCell launches regulatory development of mdc-WWM program
Apr 16, 2020: Mayne Pharma submits New Drug Application for E4/DRSP to the FDA
Mar 03, 2020: Mithra receives acceptance of marketing authorization application (MAA) to market Estelle in Belgium and Luxembourg
Feb 27, 2020: EMA accepts Richter’s Marketing Authorization Application for Estelle, a novel combined oral contraceptive
Feb 10, 2020: Mithra’s E4-based product Estelle to benefit from positive ruling on Patent Income Deduction
Dec 05, 2019: Once-A-month oral contraceptive pill in development
Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program
Oct 22, 2019: Mithra announces publication of Estelle abstracts in connection with the 13th Annual Meeting of the European Society of Gynecology
Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology
Aug 08, 2019: Mithra obtains crucial additiol Estelle patent in Japan
Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary tionwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results
Apr 02, 2019: Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle
Feb 13, 2019: Mithra successfully produces its first commercial batch of Myring for Europe
Jan 30, 2019: Mithra announces positive top-line results of Estelle phase III oral contraceptive study in U.S/Cada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Female Contraception, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Female Contraception, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Contraception - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2020
Female Contraception - Pipeline by Dare Bioscience Inc, H1 2020
Female Contraception - Pipeline by Evestra Inc, H1 2020
Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H1 2020
Female Contraception - Pipeline by Hervana Ltd, H1 2020
Female Contraception - Pipeline by Luye Pharma Group Ltd, H1 2020
Female Contraception - Pipeline by MedinCell SA, H1 2020
Female Contraception - Pipeline by Micron Biomedical Inc, H1 2020
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2020
Female Contraception - Pipeline by Mucommune LLC, H1 2020
Female Contraception - Pipeline by Navad Life Sciences Pte Ltd, H1 2020
Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H1 2020
Female Contraception - Pipeline by Ovastasis LLC, H1 2020
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
Female Contraception - Pipeline by Viramal Ltd, H1 2020
Female Contraception - Pipeline by Yaso Therapeutics Inc, H1 2020
Female Contraception - Pipeline by YourChoice Therapeutics Inc, H1 2020
Female Contraception - Dormant Projects, H1 2020
Female Contraception - Dormant Projects, H1 2020 (Contd..1), H1 2020
Female Contraception - Discontinued Products, H1 2020